Yongsheng Wang

Chengdu Yongsheng Biological Technology is a Chinese biotechnology company focused on the development of advanced cell therapies and gene-edited products for cancer treatment. The company is the corporate vehicle for the research of Professor Yongsheng Wang, a leading oncologist at West China Hospital who pioneered the world's first human clinical trial using CRISPR-Cas9 technology to treat lung cancer. Its pipeline includes various CAR-T and TCR-T cell therapies targeting solid tumors and hematological malignancies, as well as CRISPR-edited immune cell products. The company operates primarily as a research and development entity, collaborating extensively with academic institutions and hospitals to advance its clinical programs.